Both type I and type II ROS1 kinase inhibitors have inhibitory effects on ROS1 fusion‐positive tumors,80 including crizotinib in CD74‐ROS1 and SDC4‐ROS1 fusion NSCLC,81 ceritinib in TFG‐ROS1 fusion inflammatory myofibroblastoma,82 and repotrectinib in G2032R‐ROS1 and D2033N‐ROS1 fusion tumors.83 The gene discussed is SDC4; the disease is non-small cell lung carcinoma.